Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
ERO1-ALPHA INHIBITORS
Document Type and Number:
WIPO Patent Application WO/2020/142694
Kind Code:
A3
Abstract:
Provided herein are modified immune effector cells and therapies for the treatment of cancer comprising the administration of T cells in which expression of ERO1α or PERK is reduced or eliminated to a patient in need thereof.

Inventors:
THAXTON JESSICA (US)
Application Number:
PCT/US2020/012189
Publication Date:
August 13, 2020
Filing Date:
January 03, 2020
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
MUSC FOUND FOR RES DEV (US)
International Classes:
C12N9/20; C12N5/0783; C12N9/22; C12N15/113; C12N15/87
Other References:
THAXTON ET AL.: "Modulation of Endoplasmic Reticulum Stress Controls CD 4+ T- cell Activation and Antitumor Function", CANCER IMMUNOL RES, vol. 5, no. 8, 5 August 2017 (2017-08-05), pages 666 - 675, XP055730223
LI ET AL.: "Role of ER01-alpha-mediated stimulation of inositol 1,4,5-triphosphate receptor activity in endoplasmic reticulum stress-induced apoptosis", J CELL BIOL, vol. 186, no. 6, 21 September 2009 (2009-09-21), pages 783 - 792, XP055730224
TAKEI ET AL.: "Hypoxia-inducible ERO1.alpha. promotes cancer progression through modulation of integrin-beta.1 modification and signalling in HCT116 colorectal cancer cells", SCI REP, vol. 7, no. 9380, 24 August 2017 (2017-08-24), pages 1 - 11, XP055730231
Attorney, Agent or Firm:
CORCORAN, James, T. (US)
Download PDF: